Print

Featured Studies Results

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients (CORAL Study)

https://www.facingourrisk.org/research-clinical-trials/study/256 /early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05410977 (https://clinicaltrials.gov/show/NCT05410977)

Prevention
People with Lynch Syndrome at risk for colon cancer

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

The WISDOM Study: Women Informed to Screen Depending on Measures of Risk

https://www.facingourrisk.org/research-clinical-trials/study/45 /wisdom-study

Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)

Prevention
Genetic testing and breast cancer screening

MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260 /screening-in-men-at-high-risk-of-developing-prostate-cancer

Clinicaltrials.gov identifier:
NCT05608694 (https://clinicaltrials.gov/show/NCT05608694)

Prevention
Screening using MRI for men at risk of developing prostate cancer

Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

https://www.facingourrisk.org/research-clinical-trials/study/267 /observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation

Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

https://www.facingourrisk.org/research-clinical-trials/study/271 /a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca

Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women

https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)

Prevention
Prevention study for women at high risk for ovarian cancer

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245 /a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)

Treatment
Phase 2 treatment study for recurrent endometrial cancer

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281 /studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)

Prevention
Prevention study for people with Lynch syndrome

Kindred Study

https://www.facingourrisk.org/research-clinical-trials/study/255 /kindred

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors

Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

Metastatic Castration Resistant Prostate Cancer Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/240 /metastatic-castration-resistant-prostate-cancer-clinical-trial

Clinicaltrials.gov identifier:
NCT03460977 (https://clinicaltrials.gov/show/NCT03460977)

Treatment
Treatment study for men with metastatic castration resistant prostate cancer

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140 /olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Clinicaltrials.gov identifier:
NCT04858334 (https://clinicaltrials.gov/show/NCT04858334)

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180 /prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)

Prevention
People at high risk for prostate cancer due to an inherited mutation

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210 /treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141 /blood-markers-of-early-pancreas-cancer

Clinicaltrials.gov identifier:
NCT03568630 (https://clinicaltrials.gov/show/NCT03568630)

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.